Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash & Equivalents (2016 - 2025)

Editas Medicine (EDIT) has disclosed Cash & Equivalents for 11 consecutive years, with $165.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents rose 72.85% to $165.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $165.6 million, a 72.85% increase, with the full-year FY2024 number at $131.5 million, up 6.38% from a year prior.
  • Cash & Equivalents was $165.6 million for Q3 2025 at Editas Medicine, up from $138.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $354.9 million in Q1 2021 to a low of $64.4 million in Q2 2024.
  • A 5-year average of $171.0 million and a median of $141.5 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: plummeted 70.82% in 2024, then skyrocketed 114.99% in 2025.
  • Editas Medicine's Cash & Equivalents stood at $203.5 million in 2021, then plummeted by 30.46% to $141.5 million in 2022, then decreased by 12.63% to $123.7 million in 2023, then rose by 6.38% to $131.5 million in 2024, then grew by 25.93% to $165.6 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Cash & Equivalents are $165.6 million (Q3 2025), $138.5 million (Q2 2025), and $138.7 million (Q1 2025).